Humana Inc. $HUM Stock: Aberdeen Group plc Decreases Position

Humana logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group cut its Humana stake by 31.1% in the third quarter, selling 71,667 shares and ending the period with 158,744 shares worth about $60.6 million.
  • Humana reported quarterly revenue of $41.16 billion, up 26.1% year over year, and EPS of negative $0.70, beating analysts’ estimate of negative $1.00.
  • Analysts give Humana a consensus “Moderate Buy” rating and an average price target of $476.52; the company also announced a quarterly dividend of $0.885 per share.
  • MarketBeat previews top five stocks to own in December.

Aberdeen Group plc trimmed its stake in Humana Inc. (NYSE:HUM - Free Report) by 31.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 158,744 shares of the insurance provider's stock after selling 71,667 shares during the period. Aberdeen Group plc owned approximately 0.13% of Humana worth $60,572,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Humana in the second quarter worth $4,138,160,000. Pzena Investment Management LLC bought a new position in Humana in the 2nd quarter worth about $1,749,014,000. Assenagon Asset Management S.A. grew its stake in Humana by 20,126.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider's stock worth $479,053,000 after acquiring an additional 1,249,272 shares in the last quarter. Legal & General Group Plc bought a new position in Humana in the 2nd quarter worth about $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC purchased a new position in shares of Humana during the second quarter worth approximately $314,922,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Insider Activity

In related news, insider Joseph Ventura sold 5,495 shares of Humana stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the sale, the insider directly owned 21,910 shares in the company, valued at approximately $9,505,653.50. The trade was a 20.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is owned by company insiders.

Humana Trading Up 0.1%

Shares of NYSE:HUM opened at $450.38 on Monday. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $456.50. The stock has a market cap of $54.09 billion, a price-to-earnings ratio of 43.81, a PEG ratio of 2.14 and a beta of 0.65. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.61. The business has a 50-day moving average price of $408.53 and a 200-day moving average price of $316.91.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. During the same quarter in the previous year, the company posted $3.24 earnings per share. The company's revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. Equities analysts predict that Humana Inc. will post 9.66 EPS for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana's dividend payout ratio is presently 34.44%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on HUM shares. Bank of America upgraded shares of Humana from a "neutral" rating to a "buy" rating and set a $500.00 target price on the stock in a report on Wednesday, July 29th. UBS Group boosted their price target on shares of Humana from $405.00 to $495.00 and gave the company a "neutral" rating in a report on Monday, October 12th. Jefferies Financial Group restated a "buy" rating and issued a $420.00 price target on shares of Humana in a report on Friday, November 6th. Cantor Fitzgerald upped their price target on shares of Humana from $460.00 to $495.00 and gave the stock an "overweight" rating in a research report on Monday, November 9th. Finally, Truist Financial increased their price objective on shares of Humana from $415.00 to $475.00 and gave the company a "hold" rating in a research note on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $476.52.

Get Our Latest Stock Report on HUM

Humana Company Profile

(Free Report)

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Further Reading

Institutional Ownership by Quarter for Humana (NYSE:HUM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Humana Right Now?

Before you consider Humana, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.

While Humana currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines